Colin Baigent

91.3k total citations · 10 hit papers
136 papers, 22.6k citations indexed

About

Colin Baigent is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Nephrology. According to data from OpenAlex, Colin Baigent has authored 136 papers receiving a total of 22.6k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Cardiology and Cardiovascular Medicine, 46 papers in Surgery and 30 papers in Nephrology. Recurrent topics in Colin Baigent's work include Lipoproteins and Cardiovascular Health (34 papers), Antiplatelet Therapy and Cardiovascular Diseases (28 papers) and Health Systems, Economic Evaluations, Quality of Life (24 papers). Colin Baigent is often cited by papers focused on Lipoproteins and Cardiovascular Health (34 papers), Antiplatelet Therapy and Cardiovascular Diseases (28 papers) and Health Systems, Economic Evaluations, Quality of Life (24 papers). Colin Baigent collaborates with scholars based in United Kingdom, United States and Italy. Colin Baigent's co-authors include Lisa Blackwell, Anthony Keech, Jonathan Emberson, Carlo Patrono, Patricia M. Kearney, Rory Collins, Peter Sleight, Adrienne Kirby, John Simes and Christina Reith and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Colin Baigent

131 papers receiving 21.8k citations

Hit Papers

Efficacy and safety of cholesterol-lowering tre... 1988 2026 2000 2013 2005 2010 1988 2006 2015 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
    2005 5.0k citations Colin Baigent, Lisa Blackwell et al. profile →
  2. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
    2010 4.4k citations Colin Baigent, Lisa Blackwell et al. profile →
  3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    1988 2.1k citations Rory Collins, Colin Baigent et al. profile →
  4. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
    2006 1.0k citations Colin Baigent, Heather Halls et al. BMJ profile →
  5. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
    2015 1.0k citations Jonathan Emberson, Lisa Blackwell et al. profile →
  6. Low-Dose Aspirin for the Prevention of Atherothrombosis
    2005 877 citations Carlo Patrono, Colin Baigent et al. New England Journal of Medicine profile →
  7. Antiplatelet Drugs
    2008 557 citations Carlo Patrono, Colin Baigent et al. profile →
  8. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England
    2020 430 citations Chris P Gale, Martin Landray et al. profile →
  9. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients
    2023 139 citations Natalie Staplin, Jonathan Emberson et al. profile →
  10. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
    2025 16 citations François Mach, Jeanine E. Roeters van Lennep et al. Atherosclerosis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Colin Baigent United Kingdom 51 11.0k 8.9k 4.7k 3.7k 2.0k 136 22.6k
Ulf Landmesser Germany 86 10.8k 1.0× 15.2k 1.7× 4.4k 0.9× 1.8k 0.5× 3.1k 1.6× 574 34.0k
Nanette K. Wenger United States 75 10.3k 0.9× 20.5k 2.3× 6.4k 1.4× 2.8k 0.8× 1.4k 0.7× 372 35.9k
Jonathan Emberson United Kingdom 48 7.6k 0.7× 6.3k 0.7× 4.1k 0.9× 2.5k 0.7× 1.2k 0.6× 134 20.8k
Barry R. Davis United States 56 9.4k 0.9× 13.3k 1.5× 5.9k 1.3× 3.0k 0.8× 1.5k 0.7× 256 25.7k
Salim S. Virani United States 61 8.3k 0.8× 11.0k 1.2× 4.8k 1.0× 3.1k 0.8× 1.1k 0.6× 734 25.2k
Robert P. Giugliano United States 86 15.9k 1.4× 18.9k 2.1× 4.8k 1.0× 4.9k 1.3× 2.2k 1.1× 558 33.3k
Richard C. Pasternak United States 48 11.5k 1.0× 10.0k 1.1× 9.4k 2.0× 3.4k 0.9× 1.9k 0.9× 93 28.3k
Donald B. Hunninghake United States 47 11.3k 1.0× 7.5k 0.8× 9.4k 2.0× 3.5k 0.9× 2.1k 1.1× 167 26.4k
Lemuel A. Moyé United States 53 8.8k 0.8× 12.0k 1.4× 4.3k 0.9× 2.3k 0.6× 1.5k 0.7× 140 22.9k
Marc S. Sabatine United States 107 22.8k 2.1× 27.9k 3.1× 13.3k 2.8× 3.9k 1.0× 2.4k 1.2× 512 51.0k

Countries citing papers authored by Colin Baigent

Since Specialization
Citations

This map shows the geographic impact of Colin Baigent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin Baigent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin Baigent more than expected).

Fields of papers citing papers by Colin Baigent

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin Baigent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin Baigent. The network helps show where Colin Baigent may publish in the future.

Co-authorship network of co-authors of Colin Baigent

This figure shows the co-authorship network connecting the top 25 collaborators of Colin Baigent. A scholar is included among the top collaborators of Colin Baigent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colin Baigent. Colin Baigent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mach, François, Jeanine E. Roeters van Lennep, Lâle Tokgözoğlu, et al.. (2025). 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis. 409. 120479–120479. 16 indexed citations breakdown →
2.
Jüni, Peter, Sotiris Antoniou, Elena Arbelo, et al.. (2025). 2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention. European Heart Journal. 46(20). 1885–1894. 7 indexed citations
3.
Angelantonio, Emanuele Di, Lisa Pennells, Magdy Abdelhamid, et al.. (2025). 2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations II: diagnostic tests and prediction models. European Heart Journal. 46(20). 1895–1906. 2 indexed citations
4.
Herrington, William G., Charlie Harper, Natalie Staplin, et al.. (2023). Impact of Outcome Adjudication in Kidney Disease Trials: Observations From the Study of Heart and Renal Protection. Kidney International Reports. 8(8). 1489–1495. 1 indexed citations
5.
Staplin, Natalie, William G. Herrington, Federico Murgia, et al.. (2022). Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology. Hypertension. 79(12). 2671–2681. 14 indexed citations
6.
Aktaa, Suleman, Gorav Batra, Lars Wallentin, et al.. (2020). European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. European Heart Journal - Quality of Care and Clinical Outcomes. 8(1). 4–13. 42 indexed citations
7.
Hopewell, Jemma C., Alison Offer, Richard Haynes, et al.. (2020). Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. European Heart Journal. 41(35). 3336–3342. 26 indexed citations
8.
Donovan, Killian, Richard Haynes, David C. Wheeler, et al.. (2018). Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. Journal of the American Society of Nephrology. 29(7). 2015–2027. 120 indexed citations
9.
Patrono, Carlo, João Morais, Colin Baigent, et al.. (2017). Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. Journal of the American College of Cardiology. 70(14). 1760–1776. 133 indexed citations
10.
Herrington, William G., Jonathan Emberson, Natalie Staplin, et al.. (2014). The Effect of Lowering LDL Cholesterol on Vascular Access Patency. Clinical Journal of the American Society of Nephrology. 9(5). 914–919. 18 indexed citations
11.
Haynes, Richard, Natalie Staplin, Jonathan Emberson, et al.. (2014). Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases. 64(1). 40–48. 55 indexed citations
12.
Blackwell, Lisa, J. J. F. Belch, J. E. Buring, et al.. (2014). Efficacy of aspirin in people with diabetes: an individual participant data meta-analysis of 26 randomised trials. European Heart Journal. 35. 1020–1020. 1 indexed citations
13.
Reith, Christina, Martin Landray, P.J. Devereaux, et al.. (2013). Randomized Clinical Trials — Removing Unnecessary Obstacles. New England Journal of Medicine. 369(11). 1061–1065. 86 indexed citations
14.
Rahimi, Kazem, Paul McGale, William Majoni, et al.. (2009). Effect of statins on ventricular arrhythmic events: a collaborative meta-analysis of randomised controlled trials. European Heart Journal. 30. 591–591. 1 indexed citations
15.
16.
Baigent, Colin, Martin Landray, Craig Leaper, et al.. (2005). First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases. 45(3). 473–484. 146 indexed citations
17.
Baigent, Colin. (2005). Aspirin for everyone older than 50?: AGAINST. BMJ. 330(7505). 1442–1443. 13 indexed citations
18.
Roderick, Paul, Kevin C. Wilson, Heather Halls, et al.. (2005). Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technology Assessment. 9(49). iii–iv, ix. 217 indexed citations
19.
Baigent, Colin, et al.. (2004). Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. Current Opinion in Nephrology & Hypertension. 13(6). 601–605. 16 indexed citations
20.
Baigent, Colin, et al.. (2000). The adverse effects of different doses of aspirin: a systematic overview of randomised trials and observational studies. Stroke. 31. 2869–2869. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ulf Landmesser Breakdown of academic impact, for papers by Nanette K. Wenger Breakdown of academic impact, for papers by Jonathan Emberson Breakdown of academic impact, for papers by Barry R. Davis Breakdown of academic impact, for papers by Salim S. Virani Breakdown of academic impact, for papers by Robert P. Giugliano Breakdown of academic impact, for papers by Richard C. Pasternak Breakdown of academic impact, for papers by Donald B. Hunninghake Breakdown of academic impact, for papers by Lemuel A. Moyé Breakdown of academic impact, for papers by Marc S. Sabatine
Rankless by CCL
2026